CN105983051A - External traditional Chinese medicine composition and preparation with functions of relieving allergy and resisting inflammation and preparation method thereof - Google Patents
External traditional Chinese medicine composition and preparation with functions of relieving allergy and resisting inflammation and preparation method thereof Download PDFInfo
- Publication number
- CN105983051A CN105983051A CN201510085514.6A CN201510085514A CN105983051A CN 105983051 A CN105983051 A CN 105983051A CN 201510085514 A CN201510085514 A CN 201510085514A CN 105983051 A CN105983051 A CN 105983051A
- Authority
- CN
- China
- Prior art keywords
- preparation
- radix
- chinese medicine
- external
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 98
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims description 40
- 206010020751 Hypersensitivity Diseases 0.000 title abstract description 16
- 208000026935 allergic disease Diseases 0.000 title abstract description 15
- 230000007815 allergy Effects 0.000 title abstract description 14
- 206010061218 Inflammation Diseases 0.000 title abstract description 11
- 230000004054 inflammatory process Effects 0.000 title abstract description 11
- 230000006870 function Effects 0.000 title abstract description 10
- 239000000284 extract Substances 0.000 claims description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 239000000706 filtrate Substances 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 19
- 239000002994 raw material Substances 0.000 claims description 18
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 16
- 241001018563 Nekemias grossedentata Species 0.000 claims description 16
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 16
- 239000012467 final product Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000003828 vacuum filtration Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 8
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 8
- 238000002481 ethanol extraction Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000009413 insulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 34
- 238000002474 experimental method Methods 0.000 abstract description 24
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 20
- 208000003251 Pruritus Diseases 0.000 abstract description 19
- 108090001007 Interleukin-8 Proteins 0.000 abstract description 18
- 230000014509 gene expression Effects 0.000 abstract description 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 10
- 230000002757 inflammatory effect Effects 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 229960001340 histamine Drugs 0.000 abstract description 5
- 230000006698 induction Effects 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 3
- 230000007803 itching Effects 0.000 abstract description 3
- 230000002087 whitening effect Effects 0.000 abstract description 3
- 230000035699 permeability Effects 0.000 abstract description 2
- 230000000452 restraining effect Effects 0.000 abstract 4
- 230000009610 hypersensitivity Effects 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 241000759833 Cornus officinalis Species 0.000 abstract 1
- 241000563981 Nekemias megalophylla Species 0.000 abstract 1
- 208000028990 Skin injury Diseases 0.000 abstract 1
- 206010042496 Sunburn Diseases 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 28
- 239000000523 sample Substances 0.000 description 26
- 230000001629 suppression Effects 0.000 description 22
- 230000001815 facial effect Effects 0.000 description 21
- 230000008439 repair process Effects 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 102000004890 Interleukin-8 Human genes 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 206010015150 Erythema Diseases 0.000 description 15
- 102000043136 MAP kinase family Human genes 0.000 description 14
- 108091054455 MAP kinase family Proteins 0.000 description 14
- 231100000321 erythema Toxicity 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 9
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000036564 melanin content Effects 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010040844 Skin exfoliation Diseases 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 5
- 230000003266 anti-allergic effect Effects 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 230000035618 desquamation Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 229960001660 histamine phosphate Drugs 0.000 description 5
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 4
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 4
- 102100023132 Transcription factor Jun Human genes 0.000 description 4
- 206010045240 Type I hypersensitivity Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002052 anaphylactic effect Effects 0.000 description 4
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 3
- 102000009438 IgE Receptors Human genes 0.000 description 3
- 108010073816 IgE Receptors Proteins 0.000 description 3
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 3
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003448 neutrophilic effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016322 Feeling abnormal Diseases 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000863032 Trieres Species 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 238000010523 cascade reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- -1 flavone compound Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 108091005981 phosphorylated proteins Proteins 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009959 type I hypersensitivity Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102000005869 Activating Transcription Factors Human genes 0.000 description 1
- 108010005254 Activating Transcription Factors Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 206010049522 Anisochromia Diseases 0.000 description 1
- 244000139693 Arctostaphylos uva ursi Species 0.000 description 1
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101000584625 Homo sapiens Ras association domain-containing protein 9 Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 1
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100029976 Ras association domain-containing protein 9 Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 208000002440 photoallergic dermatitis Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an external traditional Chinese medicine composition with functions of relieving allergy and resisting inflammation. The composition is prepared from, by weight, 2-6 parts of Ampelopsis megalophylla Diels et Gilg, 1-4 parts of radix sileris, 1-4 parts of radix sophorae flavescentis, 1-4 parts of radix angelicae sinensis, 1-4 parts of radix ophiopogonis and 1-4 parts of cornus officinalis. It is proved through experiments that the composition is safe and free of irritation to skin, has effective allergy restraining and itching stopping functions, and has an effect on restraining I-type hypersensitivity through inhibitor IL-6, and has an effect on restraining IV-type hypersensitivity through inhibitor IL-8. By reducing the increase of expression of protein, with induction MAPKs channel ERK, of PMACI, the effect of restraining inflammatory factor high expression can be achieved, and therefore the inflammation and allergy caused by the improvement of permeability of blood capillary and the release of histamine are restrained, and the composition has a good function for other skin injuries such as sunburn. The composition has a function of whitening skin and preserving moisture and has an effect on shielding skin.
Description
Technical field
The present invention relates to a kind of external medicine composition, a kind of external application Chinese medicine with Shu Min anti-inflammatory efficacy
Compositions and the skin care formulation prepared by this external medicine composition.
Background technology
In recent years, extensive haze event is repeatedly broken out in most of China area, at Beijing area haze to healthy shadow
Sound is the topic that the public is extremely concerned about, has caused social concerns widely, and the impact of health is included many by PM2.5
Individual aspect, its general character is to suck oxidative stress, inflammatory reaction and the immune system dysfunction caused after human body, enters
And cause increasing sharply of sensitive group, and skin sensitivity is one of sign therein.Show according to domestic Epidemiological study
Showing, the sickness rate of China's anaphylactic disease is up to 37.3%, and wherein skin sensitivity crowd is about 3%, and with every 10
The speed in year 23 times increases.
Along with the progress of immunological investigation, from common food, natural plants and Chinese medicine compound, find antiallergic activity become
Being divided into domestic and international study hotspot, its mechanism of action has Mutiple Targets, multi-level feature, shows that Anaphylactic mediator is theoretical
Multiple links on, and few side effects, be clinically used for preventing and treating anaphylactic disease and also obtain good therapeutic effect.
At present, the commercially available skin care item with antiallergic effect are many based on moisturizing, can only play alleviation and control allergy effect,
Easily recurrent exerbation.And effect is single, it is impossible to solve the situations such as the anisochromia that brought by allergy while antiallergic.
Summary of the invention
The primary and foremost purpose of the present invention is to propose the Chinese medicine composition of a kind of Shu Min anti-inflammatory efficacy.
Another object of the present invention is to propose the preparation method of a kind of above-mentioned Chinese medicine composition.
The invention thinking of the present invention is:
The present invention utilizes the biotechnology of advanced person, in conjunction with the theory of Chinese medical science of Chinese tradition, by Ampelopsis grossedentata, Radix Saposhnikoviae, Radix Sophorae Flavescentis,
Together with being effectively combined in Fructus Corni Radix Angelicae Sinensis, Radix Ophiopogonis, form compound recipe, and as active component, make further
Standby become skin care formulation, its have antipruritic, press down quick, antiinflammatory and Bearberry Extract.Radix Adenophorae (Radix Glehniae) effect is increased on the basis of the party
More preferably.
Ampelopsis grossedentata, is commonly called as rattan mother-in-law's tea, Ampelopsis grossedentata, white monkey, mountain Folium hydrangeae strigosae, dragon beard tea, Tujia's manna or Tujia's god's tea etc., its
Formal name used at school is Ampelopsis grossedentata [Ampelopsis grossedentata (Hand-Mazz) W.T.wang].Main distribution
In China Hunan, Hubei, Guangxi and other places, can be not only used for treating laryngopharynx swelling and pain, cold, fever, icterohepatitis, bleb
The diseases such as furuncle, can drink by daily bubble again, cool, thirst-quenching.In Ampelopsis grossedentata, flavones content high (up to more than 40%) is in plant kingdom
In really belong to exception, polyphenol content the highest (about 20%), flavone compound and polyphenol compound have
Physiologically active widely.Modern medicine research shows, Ampelopsis grossedentata and extract oral thereof have regulation immunity, antitumor,
Antioxidation, blood fat reducing, blood pressure lowering, blood sugar lowering, protect the liver, hepatoprotective and alleviate the effects such as ethylism.
Radix Saposhnikoviae: another name copper rue, Hui Yun, return grass, Rhizoma Cibotii, hundred kinds.Herbaceos perennial, the nice and cool weather of its happiness,
Cold-resistant, drought-resistant, main product in Hebei, Heilungkiang, Sichuan, the ground such as Inner Mongol.The Gen Kesheng of Radix Saposhnikoviae uses.Acrid in the mouth,
Sweet, slightly warm in nature.There are expelling pathogenic wind from the body surface, removing dampness to relieve pain, effect of relieving convulsion.
Radix Sophorae Flavescentis: bitter in the mouth；Cold in nature.Return liver, kidney, large intestine, small intestine meridian, bladder, heart channel.There is heat clearing and damp drying, kill
Worm, effect of diuresis.
Radix Angelicae Sinensis: nature and flavor are sweet, pungent, warm.Return liver, the heart, spleen channel.Have and enrich blood；Invigorate blood circulation；Menstruction regulating and pain relieving；Moisturize cunning
Effect of intestinal.
Radix Ophiopogonis: sweet in the mouth, micro-hardship, it is slightly cold.GUIXIN, lung, stomach warp.Function with cure mainly: YIN nourishing and the production of body fluid promoting, lung moistening clears away heart-fire.
For dryness of the lung dry cough, deficiency of YIN consumptive disease is coughed, sore throat pharyngalgia, and Tianjin wound is thirsty, and interior-heat is quenched one's thirst, vexed insomnia, dryness of the intestine constipation.
Fructus Corni: another name Fructus Corni, Fructus Corni, mountain are in meat etc., for vertigo and tinnitus, soreness of waist and knee joint, impotence and seminal emission,
Enuresis frequent micturition, bleeding not during menses, profuse sweating is collapsed.
Radix Adenophorae (Radix Glehniae): sweet in the mouth, micro-hardship, cold nature.Attach to the lung and stomach meridians.There is replenishing YIN and removing heat, moistening the lung and resolving phlegm, reinforcing stomach reg fluid
Effect.
For realizing the purpose of the present invention, the present invention uses following concrete technical scheme:
A kind of external medicine composition with Shu Min anti-inflammatory efficacy, described external medicine composition is joined by following weight parts
The crude drug of ratio is made:
Ampelopsis grossedentata 2～6, Radix Saposhnikoviae 1～4, Radix Sophorae Flavescentis 1～4, Radix Angelicae Sinensis 1～4, Radix Ophiopogonis 1～4, Fructus Corni 1～4.
Another kind has the external medicine composition of Shu Min anti-inflammatory efficacy, and described external medicine composition is at above-mentioned composition
On the basis of increase Radix Adenophorae (Radix Glehniae), its weight is 1～4.
A kind of preparation method of above-mentioned external medicine composition, specifically comprising the following steps that of described preparation method
(1) weigh by described weight after above-mentioned raw materials medicated powder is broken, mixing；
(2) being 60%～95% ethanol extraction by percent by volume, crude drug and ethanol mass volume ratio g/ml are 1:
10～1:30,70 DEG C～90 DEG C are extracted 1～4 hour；
(3) extracting solution that step (2) obtains being cooled to 20 DEG C～30 DEG C, 100～200 mesh filter, and obtain filtrate；
(4) 1,3 butylene glycol adding original amount of alcohol in filtrate is miscible uniformly, and rotation steams the ethanol in solution, very
Empty sucking filtration, collects filtrate, to obtain final product.
In described step (2), the percent by volume of ethanol is 75%, and crude drug and ethanol mass volume ratio g/ml are 1:
15；70 DEG C of extraction times are 3 hours.
In described step (4), vacuum filtration condition is for spread 1.2 μm filter plates in buchner funnel, carries out vacuum filtration.
A kind of external application Chinese medicine extract with Shu Min anti-inflammatory efficacy, described external application Chinese medicine extract is extracted by said method
Obtain.
Above-mentioned external application Chinese medicine extract purposes in preparation has the external-use skin care preparation of Shu Min anti-inflammatory efficacy.
A kind of skin care formulation with Shu Min anti-inflammatory efficacy, wherein, described skin care formulation is by above-mentioned external application Chinese medicine extract
And skin care field customary adjuvant makes.
A kind of external skin-care composition with Shu Min anti-inflammatory efficacy, described external skin-care composition is by following weight percentage
The raw material composition of ratio:
The preparation method of a kind of above-mentioned skin care compositions, comprises the steps:
(1) by A phase mixes with the water in B phase with the raw material beyond Chinese medicine extract except as noted, it is heated to
90 DEG C, after adding the AVC in B phase, 30～40 DEG C are incubated 20～60 minutes,
Homogenizing；
(2) add the preservative in described external application Chinese medicine extract and B phase, homogenizing, to obtain final product.
What said method prepared is essence, and in essence, other components outside a good appetite suddenly appearing in a serious disease medicament extract are not conventional
Adjuvant, but study for a long period of time matching with Chinese medicine extract of obtaining play the composition of optimum synergistic effect through inventor.
Utilize Chinese medicine composition and skin care field conventional method that the present invention provides and adjuvant can also prepare other
Dosage form, such as cream, cosmetic water, emulsion, spray etc..This Chinese medicine composition smears skin after being simply pulverized and mixed
May also function as described effect.
The method that recommends of the preparation that the present invention provides is: imposes on human skin with smearing method, massages gently
Until absorbing.
The beneficial outcomes of the present invention:
The present invention is verified by experiments skin safe non-stimulated, has effective suppression allergy and itching-relieving efficacies, by subtracting
The effect of few IL-6 content suppression type Ⅰ hypersensitivity (immediate hypersensitivity), suppresses by reducing IL-8 content
The effect of IV type allergy (delayed hypersensitivity).The present invention is also by the MAPKs reducing PMACI induction
The increase of the protein expression of path ERK, plays the effect of suppression inflammatory factor high expressed, thus plays suppression blood capillary
Pipe permeability improves and the inflammation that causes of histamine release and the generation of allergic phenomena, also to other skins such as ultraviolet injuries
Damage has good effect.Also have effect of whitening skin and preserving moisture concurrently, play the effect of skin barrier.Raw material of the present invention obtains
Try to please easily, preparation method easy, green safety, it is easy to accepted by allergic human population, there is good application prospect and city
Field prospect.
Accompanying drawing explanation
Fig. 1 is the expression of MAPK pathway protein in Ku812 cell；
Fig. 2 is melanin content variation diagram；
Fig. 3 is skin brightness (L) variation diagram；
Fig. 4 is embodiment 4 facial treatment repair uvioresistant injury experiment result figure.
Detailed description of the invention
Medical material used in the present invention all can be commercially available from China Medicament Group Corp., meets the People's Republic of China (PRC)
2005 editions standards of pharmacopeia.Other raw materials all can be obtained by commercially available purchase, and the present invention uses the source of raw material to be shown in Table 1,
Instrument title and producer used by the present invention are shown in Table 2.
Table 1
Table 2
| Title | Model | Producer |
| Thermostat water bath | HH·S1-M | Chang'an, Beijing scientific instrument factory |
| High-speed multifunctional pulverizer | JP-400B-8 | Yongkang City nine grades of rank in the feudal regimes Trade Co., Ltd. |
| Intelligent temperature control heating stirrer | SZCL | Yu Hua Instrument Ltd. of Gongyi City |
| Rotary evaporator | RE-2000 | Shanghai Yarong Biochemical Instrument Plant |
| Circulating water type vacuum pump | SHB-Ⅲ | Zhengzhou Greatwall Scientific Industrial & Trading Co., Ltd. |
The preparation of embodiment 1 Chinese medicine composition of the present invention
(1) following raw material medicaments is weighed by described weight proportion after pulverizing, mixing；
Ampelopsis grossedentata 30g, Radix Saposhnikoviae 20g, Radix Sophorae Flavescentis 20g, Radix Angelicae Sinensis 20g, 10g Radix Ophiopogonis, Fructus Corni 10g
(2) being the ethanol extraction of 75% by percent by volume, crude drug and ethanol mass volume ratio g/ml are 1:13,
70 DEG C are extracted 3 hours；
(3) extracting solution that step (2) obtains being cooled to room temperature (20 DEG C), 100 mesh filter, and obtain filtrate；
(4) 1,3 butylene glycol adding original amount of alcohol in filtrate is miscible uniformly, spreads 1.2 μm in buchner funnel
Filter plate, carries out vacuum filtration by above-mentioned gained filtrate, collects filtrate and get final product.
The preparation of embodiment 2 Chinese medicine composition of the present invention
(1) following raw material medicaments is weighed by described weight proportion after pulverizing, mixing；
Ampelopsis grossedentata 60g, Radix Saposhnikoviae 10g, Radix Sophorae Flavescentis 40g, Radix Angelicae Sinensis 10g, 20g Radix Ophiopogonis, Fructus Corni 40g
(2) being the ethanol extraction of 95% by percent by volume, crude drug and ethanol mass volume ratio g/ml are 1:30,
90 DEG C are extracted 1 hour；
(3) extracting solution that step (2) obtains being cooled to room temperature (30 DEG C), 200 mesh filter, and obtain filtrate；
(4) 1,3 butylene glycol adding original amount of alcohol in filtrate is miscible uniformly, spreads 1.2 μm in buchner funnel
Filter plate, carries out vacuum filtration by above-mentioned gained filtrate, collects filtrate and get final product.
The preparation of embodiment 3 Chinese medicine composition of the present invention
(1) following raw material medicaments is weighed by described weight proportion after pulverizing, mixing；
Ampelopsis grossedentata 20g, Radix Saposhnikoviae 40g, Radix Sophorae Flavescentis 10g, Radix Angelicae Sinensis 40g, 40g Radix Ophiopogonis, Fructus Corni 20g
(2) being the ethanol extraction of 60% by percent by volume, crude drug and ethanol mass volume ratio g/ml are 1:10,
80 DEG C are extracted 4 hours；
(3) extracting solution that step (2) obtains being cooled to room temperature (25 DEG C), 200 mesh filter, and obtain filtrate；
(4) 1,3 butylene glycol adding original amount of alcohol in filtrate is miscible uniformly, spreads 1.2 μm filters in buchner funnel
Plate, carries out vacuum filtration by above-mentioned gained filtrate, collects filtrate and get final product.
The preparation of embodiment 4 Chinese medicine composition of the present invention
(1) following raw material medicaments is weighed by described weight proportion after pulverizing, mixing；
Ampelopsis grossedentata 30g, Radix Saposhnikoviae 20g, Radix Sophorae Flavescentis 20g, Radix Angelicae Sinensis 20g, 10g Radix Ophiopogonis, Fructus Corni 10g, Radix Adenophorae (Radix Glehniae) 10g.
(2) being the ethanol extraction of 75% by percent by volume, crude drug and ethanol mass volume ratio g/ml are 1:13,
70 DEG C are extracted 3 hours；
(3) extracting solution that step (2) obtains being cooled to room temperature (20 DEG C), 100 mesh filter, and obtain filtrate；
(4) 1,3 butylene glycol adding original amount of alcohol in filtrate is miscible uniformly, spreads 1.2 μm in buchner funnel
Filter plate, carries out vacuum filtration by above-mentioned gained filtrate, collects filtrate and get final product.
The preparation of embodiment 5 Chinese medicine composition of the present invention
(1) following raw material medicaments is weighed by described weight proportion after pulverizing, mixing；
Ampelopsis grossedentata 60g, Radix Saposhnikoviae 10g, Radix Sophorae Flavescentis 40g, Radix Angelicae Sinensis 10g, 20g Radix Ophiopogonis, Fructus Corni 40g Radix Adenophorae (Radix Glehniae) 20g.
(2) being the ethanol extraction of 95% by percent by volume, crude drug and ethanol mass volume ratio g/ml are 1:30,
90 DEG C are extracted 1 hour；
(3) extracting solution that step (2) obtains being cooled to room temperature (30 DEG C), 200 mesh filter, and obtain filtrate；
(4) 1,3 butylene glycol adding original amount of alcohol in filtrate is miscible uniformly, spreads 1.2 μm in buchner funnel
Filter plate, carries out vacuum filtration by above-mentioned gained filtrate, collects filtrate and get final product.
The preparation of embodiment 6 Chinese medicine composition of the present invention
(1) following raw material medicaments is weighed by described weight proportion after pulverizing, mixing；
Ampelopsis grossedentata 20g, Radix Saposhnikoviae 40g, Radix Sophorae Flavescentis 10g, Radix Angelicae Sinensis 40g, 40g Radix Ophiopogonis, Fructus Corni 20g Radix Adenophorae (Radix Glehniae) 40g
(2) being the ethanol extraction of 60% by percent by volume, crude drug and ethanol mass volume ratio g/ml are 1:10,
80 DEG C are extracted 4 hours；
(3) extracting solution that step (2) obtains being cooled to room temperature (25 DEG C), 200 mesh filter, and obtain filtrate；
(4) 1,3 butylene glycol adding original amount of alcohol in filtrate is miscible uniformly, spreads 1.2 μm filters in buchner funnel
Plate, carries out vacuum filtration by above-mentioned gained filtrate, collects filtrate and get final product.
The preparation of embodiment 7 essence of the present invention
Component and consumption
Preparation method
(1) raw material in addition to embodiment 1 prepares extract in A phase is mixed with the water in B phase, be heated to
90 DEG C, after adding the AVC in B phase, 30 DEG C are incubated 60 minutes, homogenizing；
(2) add embodiment 1 and prepare the preservative in extract and B phase, homogenizing, to obtain final product.
The preparation of embodiment 8 essence of the present invention
Component and consumption
Preparation method
(1) raw material in addition to embodiment 2 prepares extract in A phase is mixed with the water in B phase, be heated to
70 DEG C, after adding the AVC in B phase, 40 DEG C are incubated 20 minutes, homogenizing；
(2) add embodiment 2 and prepare the preservative in extract and B phase, homogenizing, to obtain final product.
The preparation of embodiment 9 essence of the present invention
Component and consumption
Preparation method
(1) raw material in addition to embodiment 3 prepares extract in A phase is mixed with the water in B phase, be heated to
80 DEG C, after adding the AVC in B phase, 35 DEG C are incubated 40 minutes, homogenizing；
(2) add embodiment 3 and prepare the preservative in extract and B phase, homogenizing, to obtain final product.
The preparation of embodiment 10 essence of the present invention
Component and consumption
Preparation method
(1) raw material in addition to embodiment 4 prepares extract in A phase is mixed with the water in B phase, be heated to
90 DEG C, after adding the AVC in B phase, 30 DEG C are incubated 60 minutes, homogenizing；
(2) add embodiment 4 and prepare the preservative in extract and B phase, homogenizing, to obtain final product.
Efficacy experiments of the present invention
One, embodiment 1, embodiment 2, embodiment 3 gained Chinese medicine extract A, B, C antipruritic effect are evaluated
Calculate the submitted sample itch-threshold to allergic skin itching model, provide experimental basis for evaluating sample itching-relieving efficacies.
Experimental technique:
(1) test medicine: Chinese medicine extract A, B, C that embodiment 1, embodiment 2 and embodiment 3 prepare；
(2) packet: experiment mice totally 60, is divided into embodiment 1 Chinese medicine extract A heavy dose group, middle dosage group
And small dose group, embodiment 2 Chinese medicine extract B heavy dose group, middle dosage group and small dose group, in embodiment 3 in
Medicament extract C heavy dose group, middle dosage group and small dose group, model control group often organizes 6.
(3) dose design: Chinese medicine extract by test product with 0.15mL/1cm2、0.1mL/1cm2、0.05mL/1cm2Office
Portion smears as dosage group heavy dose of, middle and small dose group.Model control group gives 0.1mL/1cm2Distilled water local is coated with
Smear.
(4) right for mouse metapedes dorsal body setae is first sent out with depilatory cream and is shaved off, for three days on end at shaving the most uniformly by experimentation
Smearing corresponding dosage by test product, model control group gives distilled water and smears.Testing the 3rd day, precision weighs histamine phosphate
In right amount, be made into 0.01% with distilled water before use, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%,
0.07%, 0.08%, 0.09%, 0.10% gradient concentration is standby.To abrade at instep shaving behind the Cavia porcellus right side with coarse sandpaper,
Area about 1cm2, local repastes medicine 1 time, drips 0.01% histamine phosphate 0.05 at abrasion after last coating 10min
ML, later every 3 minutes according to 0.01%, 0.02%, 0.03%, 0.04% ... progressive concentration, is every time
0.05mL.Until occurring that Cavia porcellus later licks right metapedes, the phosphoric acid taken finally to occur Cavia porcellus to be dripped when later licking right metapedes
Histamine total amount is itch-threshold.Calculate the diversity between each group of itch-threshold comparable group.
(5) experimental result: result shows, after using histamine phosphate to cause to itch, Cavia porcellus occurs later licking right metapedes behavior.
Using and smeared cause by test product and itch behind position, Chinese medicine extract A, B, C are remarkably improved Cavia porcellus histamine phosphate itch-threshold,
Compare with model control group and have significant difference (P < 0.01, P < 0.05).(being shown in Table 3)
Table 3 sample causes, on Cavia porcellus histamine phosphate, the impact (x ± s, n=6) reacted of itching
Note: compare with model control group, * P < 0.05, * * P < 0.01
(6) experiment conclusion
Chinese medicine extract A, B, C have good itching-relieving efficacies to skin pruritus after allergy.Inventor utilizes embodiment
4,5,6 gained Chinese medicine compositions repeat above-mentioned experimental result with above-mentioned.
Two, embodiment 1, embodiment 2, embodiment 3 gained Chinese medicine extract A, B, C suppress skin allergy efficacy assessments
(1) test medicine: embodiment 1, embodiment 2 and embodiment 3 prepare Chinese medicine extract A, B, C；
(2) packet: experiment mice totally 55, is divided into embodiment 1 Chinese medicine extract A heavy dose group, middle dosage group
And small dose group, embodiment 2 Chinese medicine extract B heavy dose group, middle dosage group and small dose group, embodiment 3 Chinese medicine
Extract C heavy dose group, middle dosage group and small dose group, blank group, model control group, often group 5.
(3) dose design
By test product with 0.15mL/1cm2、0.1mL/1cm2、0.05mL/1cm2Partial smearing is as heavy dose of, middle dose
Amount group and small dose group.Blank group and model control group give 0.1mL/1cm2Distilled water partial smearing.
(4) experimentation
First being shaved off by mouse back hair with depilatory cream, in addition to blank group, remaining is respectively organized rat back and chooses 3
Point, every some subcutaneous injection anti-DNP IgE 0.5 μ g (0.5 μ l).After 48 hours, each group rat tail vein injection
DNP-HAS 100 μ g (100 μ l) containing 4% azovan blue.At tail vein injection DNP-HAS first 1 hour,
It is administered each group of rat back, centered by the point injecting anti-DNP IgE, smears 2cm at every2The corresponding medicine of area
Thing.Within after intravenous injection DNP-HAS 30 minutes, put to death rat.Cut blue dye skin, use 1:1 acetone-normal saline
Mixed solution soaks 24h, centrifuging and taking supernatant, detects OD value with spectrophotometer at 620nm.Use azovan blue
Solution makes standard curve, calculates every rat dorsum skin dye content and PCA response inhabitation rate.The results are shown in Table 4.
(5) experimental result
Result shows, rat local skin indigo plant dye after sensitization, uses after being smeared by test product, can be significantly reduced rat by test product blue
Dye skin dye content, compares with model control group and all has significant difference (P < 0.01, P < 0.05) (being shown in Table 4)
The impact that P of Rats CA is reacted by table 4 sample
Note: blank group compares, ##P < 0.01；Compare with model control group, * P < 0.05, * * P < 0.01
(6) conclusion (of pressure testing)
Embodiment 1, embodiment 2, embodiment 3 gained Chinese medicine extract A, B, C can effectively have the suppression passive mistake of skin
Quick.Inventor utilizes embodiment 4,5,6 gained Chinese medicine composition to repeat above-mentioned experimental result with above-mentioned.
Three, the Ku812 that PAMCI is induced by embodiment 1, embodiment 2, embodiment 3 gained Chinese medicine extract A, B, C
The impact of cell IL-8, IL-6
(1) experimental principle IL-6 is a kind of multifunctional cytokine, and in blood, the mononuclear phagocyte of activation is that it is main
Originate.It is also to start the cytokine that systemic inflammatory reaction is the strongest, it is possible to inducing T cell and the increasing of B cell
Value differentiation, cell cultured supernatant produces acute phase protein etc., makes inflammatory effect amplify by cascade reaction.Virus, antibacterial
In infecting all energy inductors, IL-6 expresses increase.
IL-8 is by the cytokine of Th1 emiocytosis, main mediated cell poison and the immunne response of local inflammation-related
Auxiliary antibody generates, and participates in cellular immunization and the generation of the super quick type inflammation of delayed, and principal biological effect is chemotactic and swashs
Neutrophilic granulocyte alive, promotes lysosomal enzyme activities and the phagocytosis of neutrophilic granulocyte, to basophilic granulocyte and T cell
Also having certain chemotaxis, there is metamorphosis with IL-8 in neutrophilic granulocyte, orientation migration is to reactive site after contacting
And discharging a series of activated product, these effects may result in the reaction of body local inflammation, reaches the mesh of sterilization and damaging cells
's.
Suppression to inflammatory factor IL-6 and IL-8 shows that Chinese medicine extract has suppression by ultraviolet injury, free radical
The scytitis that oxidation, environmental pollution, hypersteatosis, antibacterial infection etc. cause, such as general red, pruritus etc..
(2) experiment material Ku812 cell is provided by Chinese Academy of Sciences's cell centre；RPMI1640, IMDM culture medium and green grass or young crops
Mycin, streptomycin are purchased from Gibco company；Hyclone is purchased from HyClone company；DMSO, PMA and A12387
Purchased from Sigma company；IL-6 and IL-8 test kit is purchased from R&D systems；μ Q μ ant enzyme mark detector is purchased from
BIO-TEK company.
(3) experimental technique sample preparation: prepare positive drug and embodiment 1, embodiment 2, reality with DMSO or distilled water
Executing example 3 gained Chinese medicine extract A, B, C, the used time is with containing 10% hyclone culture medium dilution, basic, normal, high concentration
For 10mg/mL, 40mg/mL, 60mg/mL.
By the IMDM culture medium containing 10% hyclone, Ku812 cell density is adjusted to 2.2 × 106The cell of individual/mL
Suspension, is inoculated in 96 orifice plates, every hole 200 μ L.If cell blank matched group, model group, positive drug group and be subject to
Reagent thing group, often group sets 3 parallel holes, 37 DEG C, 5%CO2Incubator is cultivated and is stood 10min, positive drug and by reagent
Thing group adds positive drug and test medicine, final concentration of 50 μ g/mL, puts pre-temperature in incubator and incubates, except thin after 15min
Outside born of the same parents' blank group, each group cell adds stimulant PMA, A12387 makes final concentration be respectively 5nm, 1 μm, and cell is empty
White group adds same volume DMSO culture medium Han isoconcentration.Centrifugal separating cell after 2h, collects cell supernatant, measures
IL-8, IL-6 content in supernatant.
(4) experimental result: the basic, normal, high concentration of calculation composition A is respectively as follows: 16.9% to IL-6 suppression ratio, 22.6%,
59.7%；IL-8 suppression ratio is respectively as follows: 11.7%, 28.0%, 50.6%；The basic, normal, high concentration pair of compositions B
IL-6 suppression ratio is respectively as follows: 14.5%, 47.8%, 67.5%；IL-8 suppression ratio is respectively as follows: 7.3%, 34.8%,
44.6%；Compositions C is respectively as follows: 29.6%, 34.8%, 65.7% to IL-6 suppression ratio；To IL-8 suppression ratio respectively
For: 29.6%, 33.9%, 47.9%.Show embodiment 1, embodiment 2, embodiment 3 gained Chinese medicine composition A, B,
C can play the effect of suppression type Ⅰ hypersensitivity (immediate hypersensitivity) by suppression IL-6, by suppression IL-8
Play the effect of suppression IV type allergy (delayed hypersensitivity).And can be risen by suppression IL-6 and IL-8
Effect to treatment ultraviolet injury.Specific experiment numerical value is shown in Table 5.Inventor utilizes in embodiment 4,5,6 gained
Drug composition repeats above-mentioned experimental result with above-mentioned.
Table 5 sample IL-6, IL-8 measurement result
aStudent ' s t-test compares p < 0.01 with model group
Four, MAPKs signal path associated protein p38, ERK, and JNK are expressed by embodiment 1 gained Chinese medicine composition A
Impact
(1) experiment material Ku812 cell is provided by Chinese Academy of Sciences's cell centre；RPMI1640, IMDM culture medium and green grass or young crops
Mycin, streptomycin are purchased from Gibco company；Hyclone is purchased from HyClone company；DMSO、PMA、A12387
Purchased from Sigma company；MAPK test kit is purchased from CST company.
(2) experimental technique is with DMSO compositions formulated sample solution (200 μ g/mL, 300 μ g/mL).With containing 10%
Ku812 cell density is adjusted to 1.5 × 10 by the IMDM culture medium of hyclone6The cell suspension of individual/mL, is inoculated in
6 orifice plates, every hole 2mL.If cell blank matched group (C), model group (M), composition sample variable concentrations group,
37 DEG C, 5%CO2Incubator is cultivated and is stood 10min, adds sample solution, and final concentration is respectively 40mg/mL (S1),
60mg/mL (S2), puts pre-temperature in incubator and incubates, and after 15min in addition to cell blank group, each group cell adds stimulant
PMA, A12387 make final concentration be respectively 5nm, 1 μm, and cell blank group adds same volume and cultivates containing isoconcentration DMSO
Base.Centrifugal separating cell after 1h, collects cell, adds lysate, carries out Western Blot analysis.
(3) experimental result is as it is shown in figure 1, model group phosphorylated protein under stimulant effect is expressed and increased, sample sets
Change with model group is basically identical, and composition concentration is 200 μ g/mL (S1), it is possible to decrease MAPKs path ERK
Protein expression, to p38, JNK without impact, when composition concentration is 300 μ g/mL (S2), to MAPKs path
P38, ERK, and JNK phosphorylated protein is expressed and is had no appreciable impact.
(4) brief summary and discussion
PMACI induction Ku812 cell IL-8, IL-6 high expressed experiment in, high, medium and low concentration by test product
The expression of inflammatory factor IL-8 and IL-6 can be significantly inhibited.To the egg of p38, ERK and JNK in MAPK signal path
The testing result hint of white expression, may be suppressed inflammatory factor by reducing the protein expression of ERK by test product
Express.
Human peripheral basophil KU812 is often used as studying anaphylactoid effector lymphocyte.At KU812 cell surface
Having the IgE receptor (Fc ε RI) of high-affinity, IgE with the Fc ε RI that B cell produces is combined and causes KU812 to release
Put inflammatory mediator IL-6, histamine etc..One of IL-6 core member being referred to as cytokine, is to be produced by various kinds of cell
Raw a kind of stimulating factor with various biological activity, IL-6 can improve IL-8 expression and IgE produces and joins
With immunne response, significantly improve at allergic phenomenas such as contact dermatitis, asthma and rheumatic arthritis.
Mitogen activated protein kinase (MAPKs) signal transduction pathway is the signal of interest path participating in inflammatory reaction,
The tumor necrosis factor receptor-associated factor (TRAF6) of oligomerization is the signal of interest molecule activating MAPKs path.
MAPKs family is a class serine/threonine protein kitase, can pass through in extracellular signal transduction to cell and core
Conservative three-stage cascade reaction (MAPKKK-MAPKK-MAPK) activating transcription factor, regulator gene is expressed.This path is deposited
It is in most cells, and relevant to various kinds of cell function, may participate in cell movement, apoptosis, break up and grow increasing
The various physiological processes such as grow.4 MAPK signal transduction pathways are had determined that at present: extracellular signal-regulated kinase (ERK)
Signal path, c-Jun N end kinases (JNK)/stress-activated protein (SAPK) signal path, p38MAPK signal
Path and ERK5/ big mitogen-activated kinase (BMK1) signal path.Every signal paths all has highly special
The opposite sex, has independent function.Some degree also exists between several signal paths certain cross-talk (crosstalk).
All paths are all to be presented certain transcriptional activity by under certain specific ambient pressure.The stimulation of PMACI can swash
The two point position phosphorylation of ERK1/2, p38, JNK/MAPK alive, makes c-Jun and c-fos transcribe increase, thus increases
C-Jun and c-fos protein expression, and c-Jun and c-fos of phosphorylation can be with many cytokine promoter districts
AP-1 site combine, signal, lures in core so that expressions of inflammation-related genes increases from the transduction of core surface receptor
Lead inflammatory cytokine such as IL-1, IL-6, IL-8, IL-12, TNF-α, interferon (IFN) and adhesion molecule etc.
The expression of gene, so cause telangiectasis, vascular permeability to increase, mucosa swelling, contact dermatitis, heavy breathing
Breathe heavily, the generation of the allergic phenomena such as rheumatic arthritis.
Originally test result indicate that: the Chinese medicine extract A that embodiment 1 prepares may be by reducing PMACI induction
The increase of the protein expression of MAPKs path ERK, plays the effect of suppression inflammatory factor high expressed, thus plays suppression
Capillary permeability improves and histamine release.Illustrate that the present invention is to ultraviolet injury skin, pox skin, allergy
Property skin has good therapeutical effect.The Chinese medicine extract that inventor utilizes again embodiment 2 to 6 to prepare repeats
Above-mentioned experiment, result is with embodiment 1.
Five, the facial treatment repair white-skinned face function experiment of embodiment 7 preparation
1. experimental principle
Human experimentation, is formed test population by particular experiment crowd, and test experimenter makes to apply some make up (and cosmetics
Functional component) before and after the change of skin color, so that it is determined that the white-skinned face function of cosmetics (or functional component).
2. experimental apparatus and sample
Instrument: dermal melanin and haemachrome tester (Mexameter MX18, CK electronics corporation of Germany produces)；
Lab color difference meter (MPA9, CK electronics corporation of Germany produces).
Sample: the essence that embodiment 7 prepares.
3. Subject Population and the testing time
Totally 30 people, the age is between 30～55 years old.
Volunteer uses the time: respectively smear the facial treatment repair of twice embodiment 4 preparation every day.
Testing time: test in a week once, is tested 4 weeks.
4. experimental technique
(1) before experimenter smears sample, first examination Test sites is cleaned, after drying, smear sample.Experimenter is left and right
The tested region of inboard arm and control zone, respectively determine that the area of 4 × 4cm size is as Test sites.
(2) the appropriate essence of experimenter is coated with and is uniformly put on test zone.Experimenter uses bare substrate in check plot simultaneously
Territory, respectively smears twice every day.During experiment, experimenter can not smear any cosmetics at Test sites.
(3) experimenter's the most same time after continuously using sample, use dermal melanin and haemachrome tester with
The change of Lab color difference meter test skin color, averages.
(4) statistics every time surveyed numerical value, melanin content value processing method: 1) matched group and sample sets melanin content
T check analysis, 2) matched group and the change of sample sets skin brightness；
5. interpretation of result
(1) melanin content mutation analysis
1. found out by Fig. 2, before using sample, sample sets and the matched group melanin content indifference opposite sex；Make at sample
With rear, more all there is significant difference in each time period sample sets compared with matched group melanin content.
2. after sample sets uses 1 week compared with matched group, there is diversity significantly, melanin content substantially reduces；
Sample sets suppresses melanin effect obvious in 4 weeks, and persistence is good.
(2) skin brightness (L) change
L characterizes skin brightness, and its value is the biggest, and color is more partial to white.
From figure 3, it can be seen that sample sets relative comparison group, L-value change in first week is inconspicuous, 2～4 weeks sample sets L
Value substantially increases.
6. conclusions and recommendations
The essence that inventor prepares by embodiment 8 to 10 does above-mentioned test equally, and result is with embodiment 7 testing result.
Show according to above result of the test:
(1), after sampling, there is the lasting effect in preferable suppression melanin ability, and 4 weeks good.
(2) sampling first week, the DeGrain of its increase skin brightness, 2～4 weeks on probation, it increased skin
The effect of skin brightness is notable.
Illustrate that this sample can effectively promote the whitening effect of existing product, carry out basic platform for later stage skin protection.
Six, embodiment 7 facial treatment repair antiallergic eficac Clinical checking
Experimental technique: patient source is China department of Chinese medicine institute acupuncture hospital dermatology department out-patient.
This group totally 36 example, male 4 examples, female 32 example, the oldest 58 years old, minimum 21 years old.The course of disease is the longest 2 years,
The shortest 1 month.
Clinic mainly shows as there is discomfort when face, hands, lower limb, pedal skin, itches, and desquamation especially uses cosmetic
After product, a series of symptom occur, difficulty is more repeatedly.
Only for the crowd based on face of sensitive group, cosmetics can be with user.
Get rid of severe allergy, systemic anaphylaxis and other there is the patient of medical sign disease.
Methods of clinical observation and criterion of therapeutical effect
1, sample using method:
After every day cleansing milk face cleaning, be coated with embodiment 4 facial treatment repair at face and sensitive part appropriate, the most each the most once.
1 week, 2 weeks, 3 weeks, 4 weeks (1 month) respectively statistics once.
2, curative effect determinate standard
(1) cure: clinical symptom disappearance, condition susceptible disappear；
(2) effective: clinical symptom relief, condition susceptible disappear or disappear, and reduce or reduce；
(3) invalid: clinical symptoms, condition susceptible have no improvement.
Clinical observation result and conclusion
1, result
The situation of the total situation of embodiment 7 facial treatment repair clinical observation and experimenter's Symptoms and curative effect refer to table 6,
Table 7.
The table 6 embodiment 7 total situation of facial treatment repair clinical observation
Table 7 embodiment 7 facial treatment repair experimenter's Symptoms and the situation of curative effect
| Symptom | Symptoms (example) | Disappear (example) | Alleviate (example) | Invalid (example) |
| Itch | 36 | 27 | 6 | 3 |
| Erythema | 36 | 30 | 6 | 0 |
| Dry, desquamation | 36 | 33 | 3 | 0 |
| Sensation of pricking | 35 | 29 | 5 | 1 |
| Burning sensation | 31 | 10 | 20 | 1 |
| Bellding light | 5 | 1 | 2 | 2 |
| Blister | 1 | 0 | 0 | 1 |
| Dark yellow | 14 | 10 | 2 | 2 |
2, clinical effectiveness analysis
(1) for skin of face sensitive group skin of face cardinal symptom, (itch, erythema, dry desquamation situation use real
Executing example 7 facial treatment repair 1 week to effective percentage up to 91.7% (33 example), the cure rate of 1 month is 75% (27 example).
(2) trier's overall assessment to Application Example 4 facial treatment repair:
A, " feeling the best, be worth application " account for 77.8% (28 example)；
B, " still can feeling, can apply " account for 8.3% (3 example)；
C, " sensation general, available can " account for 13.9% (5 example)；
D, " feeling bad, be unworthy application " account for 2.7% (1 example).
(3) as long as adhering to that use is the most notable to sensitive skin crowd's therapeutic effect.
The essence that inventor prepares by embodiment 8 to 10 does above-mentioned test equally, and result is with embodiment 7 testing result.
Seven, embodiment 10 facial treatment repair antiallergic eficac Clinical checking
Experimental technique: patient source is China department of Chinese medicine institute acupuncture hospital dermatology department out-patient.
This group totally 40 example, male 6 examples, female 34 example, the oldest 55 years old, minimum 18 years old.The course of disease is the longest 2 years,
The shortest 1 month.
Clinic mainly shows as there is discomfort when face, hands, lower limb, pedal skin, itches, and desquamation especially uses cosmetic
After product, a series of symptom occur, difficulty is more repeatedly.
Only for the crowd based on face of sensitive group, cosmetics can be with user.
Get rid of severe allergy, systemic anaphylaxis and other there is the patient of medical sign disease.
Methods of clinical observation and criterion of therapeutical effect
1, sample using method:
After every day cleansing milk face cleaning, be coated with embodiment 4 facial treatment repair at face and sensitive part appropriate, the most each the most once.
1 week, 2 weeks, 3 weeks, 4 weeks (1 month) respectively statistics once.
2, curative effect determinate standard
(1) cure: clinical symptom disappearance, condition susceptible disappear；
(2) effective: clinical symptom relief, condition susceptible disappear or disappear, and reduce or reduce；
(3) invalid: clinical symptoms, condition susceptible have no improvement.
Clinical observation result and conclusion
1, result
The situation of the total situation of embodiment 10 facial treatment repair clinical observation and experimenter's Symptoms and curative effect refer to table 8,
Table 9.
The table 8 embodiment 10 total situation of facial treatment repair clinical observation
Table 9 embodiment 10 facial treatment repair experimenter's Symptoms and the situation of curative effect
| Symptom | Symptoms (example) | Disappear (example) | Alleviate (example) | Invalid (example) |
| Itch | 40 | 36 | 3 | 1 |
| Erythema | 40 | 35 | 5 | 0 |
| Dry, desquamation | 40 | 36 | 4 | 0 |
| Sensation of pricking | 39 | 33 | 5 | 1 |
| Burning sensation | 40 | 9 | 30 | 1 |
| Bellding light | 5 | 2 | 3 | 0 |
| Blister | 1 | 0 | 0 | 1 |
| Dark yellow | 15 | 9 | 4 | 2 |
2, clinical effectiveness analysis
(1) trier's overall assessment to Application Example 10 facial treatment repair:
A, " feeling the best, be worth application " account for 82.5% (33 example)；
B, " still can feeling, can apply " account for 7.5% (3 example)；
C, " sensation general, available can " account for 7.5% (3 example)；
D, " feeling bad, be unworthy application " account for 2.5% (1 example).
(2) as long as adhering to that use is the most notable to sensitive skin crowd's therapeutic effect.
Eight, embodiment 7, the damage eficac Clinical checking of embodiment 10 facial treatment repair uvioresistant
Suppression skin erythema test
This experiment is all through the agreement of each tester.
MED (minimal erythema dose), is to cause skin to produce firm visible erythema institute in fixing condition (light source and distance)
The time needed or millijoule/square centimeter (mJ/cm2).It is the basis of photo patch test that med value must measure, basis at this
On can detect further caused by photosensitive agent light poison and photoallergy.Assay method: randomly select healthy without ultraviolet
Line allergies person 30 people, before experiment, by clean by clean water for 30 volunteers (man: 13, female: 17) upper arm,
Enter at Medial upper arm with GS2006 type MULTI-WAVELENGTHRANGE SPF TESTER (multi-wavelength SPF tester)
OK.The each hole of dose irradiation 2 hours being incremented by by ladder, afterwards every 6 hours observed results.Determine everyone MED
Value.
Experiment uses in advance at upper arm surface smear embodiment 7, embodiment 10 facial treatment repair, after different according to everyone
Med value is irradiated to erythema producing, and observes every 6 hours afterwards.
As shown in Figure 4, embodiment 7 and embodiment 10 facial treatment repair uvioresistant damage results show: do not use elite
Element, erythema time of origin is less than 12 hours 9 people, uses embodiment 7 facial treatment repair, and erythema time of origin is less than
The minimizing of 12 hours is to 4 people；Erythema time of origin was extended to 18 hours numbers by 12 hours and is increased to 12 people by 4 people.
The essence that inventor prepares by embodiment 8,9 repeats above-mentioned experimental result ibid.
Embodiment 10 facial treatment repair uvioresistant damage results shows: do not use essence, erythema time of origin to be less than
12 hours 9 people, use essence, and the minimizing less than 12 hours of the erythema time of origin is to 2 people；Erythema time of origin
Extended to 18 hours numbers by 12 hours and increased to 14 people by 4 people.Show the present invention can be obviously prolonged erythema produce time
Between, i.e. postpone the generation of UV-induced skin erythema.
Claims (10)
1. an external medicine composition with Shu Min anti-inflammatory efficacy, it is characterised in that described external medicine composition
It is made up of the crude drug of following weight parts proportioning:
Ampelopsis grossedentata 2～6, Radix Saposhnikoviae 1～4, Radix Sophorae Flavescentis 1～4, Radix Angelicae Sinensis 1～4, Radix Ophiopogonis 1～4, Fructus Corni 1～4.
2. an external medicine composition with Shu Min anti-inflammatory efficacy, it is characterised in that described external medicine composition
It is made up of the crude drug of following weight parts proportioning:
Ampelopsis grossedentata 2～6, Radix Saposhnikoviae 1～4, Radix Sophorae Flavescentis 1～4, Radix Angelicae Sinensis 1～4, Radix Ophiopogonis 1～4, Fructus Corni 1～4,
Radix Adenophorae (Radix Glehniae) 1～4.
3. the preparation method of external medicine composition described in a claim 1 or 2, it is characterised in that described system
Preparation Method comprises the steps:
(1) crude drug described in claim 1 or 2 is weighed by described weight after pulverizing, mixing；
(2) being 60%～95% ethanol extraction by percent by volume, crude drug and ethanol mass volume ratio g/ml are 1:
10～1:30,70 DEG C～90 DEG C are extracted 1～4 hour；
(3) extracting solution that step (2) obtains being cooled to 20 DEG C～30 DEG C, 100～200 mesh filter, and obtain filtrate；
(4) 1,3 butylene glycol adding original amount of alcohol in filtrate is miscible uniformly, and rotation steams the ethanol in solution, very
Empty sucking filtration, collects filtrate, to obtain final product.
4. preparation method as claimed in claim 3, it is characterised in that the volume hundred of ethanol in described step (2)
Proportion by subtraction is 75%, and crude drug and ethanol mass volume ratio g/ml are 1:15；70 DEG C of extraction times are 3 hours.
5. preparation method as claimed in claim 3, it is characterised in that vacuum filtration condition in described step (4)
For spreading 1.2 μm filter plates in buchner funnel, carry out vacuum filtration.
6. an external application Chinese medicine extract with Shu Min anti-inflammatory efficacy, it is characterised in that described external application Chinese medicine extracts
Thing is extracted by preparation method described in any one in claim 3 to 5 and obtains.
7. external application Chinese medicine extract described in claim 6 is in preparation has the external-use skin care preparation of Shu Min anti-inflammatory efficacy
Purposes.
8. an external-use skin care preparation with Shu Min anti-inflammatory efficacy, it is characterised in that described external-use skin care preparation by
External application Chinese medicine extract described in claim 6 and skin care field customary adjuvant are made.
9. an external skin-care composition with Shu Min anti-inflammatory efficacy, it is characterised in that described external skin-care composition
It is made up of the raw material of following weight percentage ratio:
A phase:
B phase: AVC 0.20～1.00wt%
Preservative 0.20～1.00wt%
Water surplus.
10. the preparation method of external skin-care composition described in a claim 9, it is characterised in that described preparation side
Method comprises the steps:
(1) raw material in addition to external application Chinese medicine extract described in claim 6 in A phase is mixed with the water in B phase,
It is heated to 70～90 DEG C, adds 30～40 DEG C of insulations after the AVC in B phase
20～60 minutes, homogenizing；
(2) add external application Chinese medicine extract described in claim 6 and the preservative in B phase, homogenizing, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510085514.6A CN105983051A (en) | 2015-02-16 | 2015-02-16 | External traditional Chinese medicine composition and preparation with functions of relieving allergy and resisting inflammation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510085514.6A CN105983051A (en) | 2015-02-16 | 2015-02-16 | External traditional Chinese medicine composition and preparation with functions of relieving allergy and resisting inflammation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105983051A true CN105983051A (en) | 2016-10-05 |
Family
ID=57038480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510085514.6A Pending CN105983051A (en) | 2015-02-16 | 2015-02-16 | External traditional Chinese medicine composition and preparation with functions of relieving allergy and resisting inflammation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105983051A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108210396A (en) * | 2018-03-31 | 2018-06-29 | 佛山文森特知识产权服务有限公司 | A kind of three insured wet skin care compositions and its application |
| CN108904719A (en) * | 2018-08-15 | 2018-11-30 | 佛山市三水区嘉华化学研究院（普通合伙） | A kind of root bark of Chinese wolf-berry spermine alkaloid anti-inflammatory agent and preparation method thereof |
| CN109381411A (en) * | 2018-12-29 | 2019-02-26 | 广州优刻生物科技有限公司 | A kind of composition of anti-aging, preparation method and the cosmetics containing the composition |
| CN112791038A (en) * | 2020-03-05 | 2021-05-14 | 上海友仁生物科技有限公司 | Cosmetic composition for anti-allergy repair and preparation method thereof |
| CN113209156A (en) * | 2021-03-25 | 2021-08-06 | 山西普德药业有限公司 | Ginseng composite traditional Chinese medicine composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102018797A (en) * | 2010-11-26 | 2011-04-20 | 新时代健康产业（集团）有限公司 | Traditional Chinese medicine composition with allergy soothing effect, preparation and preparation method thereof |
| CN102430035A (en) * | 2011-12-06 | 2012-05-02 | 北京工商大学 | Chinese medicinal composition and preparation with effects of relieving allergy and itching and preparation methods thereof |
-
2015
- 2015-02-16 CN CN201510085514.6A patent/CN105983051A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102018797A (en) * | 2010-11-26 | 2011-04-20 | 新时代健康产业（集团）有限公司 | Traditional Chinese medicine composition with allergy soothing effect, preparation and preparation method thereof |
| CN102430035A (en) * | 2011-12-06 | 2012-05-02 | 北京工商大学 | Chinese medicinal composition and preparation with effects of relieving allergy and itching and preparation methods thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108210396A (en) * | 2018-03-31 | 2018-06-29 | 佛山文森特知识产权服务有限公司 | A kind of three insured wet skin care compositions and its application |
| CN108904719A (en) * | 2018-08-15 | 2018-11-30 | 佛山市三水区嘉华化学研究院（普通合伙） | A kind of root bark of Chinese wolf-berry spermine alkaloid anti-inflammatory agent and preparation method thereof |
| CN109381411A (en) * | 2018-12-29 | 2019-02-26 | 广州优刻生物科技有限公司 | A kind of composition of anti-aging, preparation method and the cosmetics containing the composition |
| CN112791038A (en) * | 2020-03-05 | 2021-05-14 | 上海友仁生物科技有限公司 | Cosmetic composition for anti-allergy repair and preparation method thereof |
| CN113209156A (en) * | 2021-03-25 | 2021-08-06 | 山西普德药业有限公司 | Ginseng composite traditional Chinese medicine composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041173B (en) | Traditional Chinese medicine external preparation for curing dermatitis and eczema and preparing method thereof | |
| CN102178844B (en) | Oral Chinese medicine preparation for treating gum swelling and pain and preparation method thereof | |
| CN102139030B (en) | Oral Chinese herbal preparation for treating gingivitis and preparation method thereof | |
| CN102178804B (en) | Chinese medicinal composition for treating perianal eczema and preparation method thereof | |
| CN105983051A (en) | External traditional Chinese medicine composition and preparation with functions of relieving allergy and resisting inflammation and preparation method thereof | |
| CN103041184B (en) | Traditional Chinese medicine composition for external use for curing chronic eczema of children and preparation method thereof | |
| CN103751663B (en) | A kind of Chinese medicine for external application treating anal eczema and preparation method thereof | |
| CN110327438A (en) | One kind is releived massage cream | |
| CN101856384B (en) | Liver-protecting combination | |
| CN106421219A (en) | Ointment for treating chronic eczema and preparation method thereof | |
| CN104784466A (en) | External traditional Chinese medicine composition with effects of relieving allergy and resisting irritation and preparation method of composition | |
| CN105497261A (en) | Matrix of patch for external use and patch and sleeping-aid patch made from matrix | |
| CN107912773A (en) | A kind of preparation for being used to alleviate physical fatigue | |
| CN104666873A (en) | Externally applied traditional Chinese medicinal composition with anti-sensitivity, itching relieving and anti-inflammatory effects, preparation and preparation method of externally applied traditional Chinese medicinal composition | |
| CN102008083B (en) | Health food for alleviating physical fatigue and removing chloasma | |
| CN103721138B (en) | A kind of traditional Chinese medicine for external application and its preparation method treating rosacea | |
| CN104706953A (en) | Traditional Chinese medicine preparation for treating chronic cervicitis | |
| KR101511699B1 (en) | Composition for improving atopic dermatitis containing mineral water | |
| CN103054991B (en) | Traditional Chinese medicine composition for treating lower abdominal discomfort, as well as preparation method and use thereof | |
| CN104758358A (en) | Medicine composite used for eczema and preparation method thereof | |
| CN108497225A (en) | A kind of plant beverage and preparation method with function of physical fatigue alleviation | |
| CN104857371A (en) | Medicine for treating colon cancer and preparation method thereof | |
| CN106074333A (en) | A kind of Ganoderma spore powder with cellular wall broken Venenum apis Mel propolis facial cream and production method thereof | |
| CN104940524A (en) | Medicine for treating leucoderma and preparation method thereof | |
| CN105770115A (en) | Traditional Chinese medicine ointment for treating eczema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161005 |
|
| RJ01 | Rejection of invention patent application after publication |